Progress in acetylcholinesterase inhibitors for Alzheimer’s disease

Bibliography

• ALZHEIMER A, STELZMANN RA, SCHNITZLEIN HN, MURTAGH FR: An English translation of Alzheimer’s 1907 paper, ‘Uber eine eigenartige Erkankung der Hirnrinde’. Clin. Anat. (1995) 8(6):429-431.
   PubMedGoogle Scholar
• THOMPSON LA, BRONSON JJ, ZUSI FC: Progress in the discovery of BACE inhibitors. Curr. Pharm. Des. (2005) 11(26):3383-3404.
   PubMedGoogle Scholar
• CHURCHER I, BEHER D: γ-Secretase as a therapeutic target for the treatment of Alzheimer’s disease. Curr. Pharm. Des. (2005) 11(26):3363-3382.
   PubMed Web of Science ®Google Scholar
• FERRER I, GOMEZ-ISLA T, PUIG B et al.: Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr. Alzheimer. Res. (2005) 2(1):3-18.
   PubMedGoogle Scholar
• MATTSON MP: Pathways towards and away from Alzheimer’s disease. Nature (2004) 430(7000):631-639.
   PubMed Web of Science ®Google Scholar
• CITRON M: Strategies for disease modification in Alzheimer’s disease. Nat. Rev. Neurosci. (2004) 5(9):677-685.
   PubMed Web of Science ®Google Scholar
• LLEO A, GREENBERG SM, GROWDON JH: Current pharmacotherapy for Alzheimer’s disease. Ann. Rev. Med. (2006) 57:513-533.
   PubMedGoogle Scholar
• ROSENBERG RN: Translational research on the way to effective therapy for Alzheimer’s disease. Arch. Gen. Psychiatry (2005) 62(11):1186-1192.
   PubMed Web of Science ®Google Scholar
• IBACH B, HAEN E: Acetylcholinesterase inhibition in Alzheimer’s disease. Curr. Pharm. Des. (2004) 10(3):231-251.
   PubMed Web of Science ®Google Scholar
• ELLIS JM: Cholinesterase inhibitors in the treatment of dementia. J. Am. Osteopath. Assoc. (2005) 105(3):145-158.
   PubMedGoogle Scholar
• SMALL DH: Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer’s disease: do we need new inhibitors? Expert Opin. Emerg. Drugs (2005) 10(4):817-825.
   PubMedGoogle Scholar
• TERRY AV Jr. BUCCAFUSCO JJ: The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. (2003) 306(3):821-827.
   PubMed Web of Science ®Google Scholar
• MULLER DM, MENDLA K, FARBER SA, NITSCH RM: Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci. (1997) 60(13-14):985-991.
   PubMed Web of Science ®Google Scholar
• FISHER A, PITTEL Z, HARING R et al.: M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: implications in future therapy. J. Mol. Neurosci. (2003) 20(3):349-356.
   PubMed Web of Science ®Google Scholar
• INESTROSA NC, ALVAREZ A, PEREZ CA et al.: Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron (1996) 16(4):881-891.
   PubMed Web of Science ®Google Scholar
• DE FERRARI GV, CANALES MA, SHIN I et al.: A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry (2001) 40(35):10447-10457.
   PubMed Web of Science ®Google Scholar
• SOREQ H, SEIDMAN S: Acetylcholinesterase-new roles for an old actor. Nat. Rev. Neurosci. (2001) 2(4):294-302.
   PubMed Web of Science ®Google Scholar
• SILMAN I, SUSSMAN JL: Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. Curr. Opin. Pharmacol. (2005) 5(3):293-302.
   PubMed Web of Science ®Google Scholar
• RECANATINI M, CAVALLI A: Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer’s disease. Expert Opin. Ther. Patents (2002) 12(12):1853-1865.
   Web of Science ®Google Scholar
• DORRONSORO I, CASTRO A, MARTINEZ A: Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. Expert Opin. Ther. Patents (2003) 13(11):1725-1732.
   Web of Science ®Google Scholar
• DU DM, CARLIER PR: Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer’s disease. Curr. Pharm. Des. (2004) 10(25):3141-3156.
   PubMed Web of Science ®Google Scholar
• BALLARD CG, GREIG NH, GUILLOZET-BONGAARTS AL, ENZ A, DARVESH S: Cholinesterases: roles in the brain during health and disease. Curr. Alzheimer. Res. (2005) 2(3):307-318.
   PubMedGoogle Scholar
• MESULAM MM, GEULA C: Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. (1994) 36(5):722-727.
   PubMed Web of Science ®Google Scholar
• GUILLOZET AL, SMILEY JF, MASH DC, MESULAM MM: Butyrylcholinesterase in the life cycle of amyloid plaques. Ann. Neurol. (1997) 42(6):909-918.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO H, YAMANISHI Y, IIMURA Y, KAWAKAMI Y: Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr. Med. Chem. (2000) 7(3):303-339.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO H, YAMANISHI Y, OGURA H, IIMURA Y, YAMATSU K: [Discovery and development of donepezil hydrochloride for the treatment of Alzheimer’s disease]. Yakugaku Zasshi (1999) 119(2):101-113.
   PubMedGoogle Scholar
• INOUE A, KAWAI T, WAKITA M et al.: The simulated binding of (+/-)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]meth yl] -1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure–activity analyses. J. Med. Chem. (1996) 39(22):4460-4470.
   PubMedGoogle Scholar
• KAWAKAMI Y, INOUE A, KAWAI T et al.: The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg. Med. Chem. (1996) 4(9):1429-1446.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO H, IIMURA Y, YAMANISHI Y, YAMATSU K: Synthesis and structure–activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. (1995) 38(24):4821-4829.
   PubMed Web of Science ®Google Scholar
• SELTZER B: Donepezil: a review. Expert Opin. Drug Metabol. Toxicol. (2005) 1(3):527-536.
   PubMedGoogle Scholar
• ROMAN GC, ROGERS SJ: Donepezil: a clinical review of current and emerging indications. Expert Opin. Pharmacother. (2004) 5(1):161-180.
   PubMed Web of Science ®Google Scholar
• JACKSON S, HAM RJ, WILKINSON D: The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br. J. Clin. Pharmacol. (2004) 58(Suppl. 1):1-8.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO H, OGURA H, ARAI Y, IIMURA Y, YAMANISHI Y: Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. (2002) 89(1):7-20.
   PubMedGoogle Scholar
• SAXENA A, FEDORKO JM, VINAYAKA CR et al.: Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases. Eur. J. Biochem. (2003) 270(22):4447-4458.
   PubMedGoogle Scholar
• BARTOLINI M, BERTUCCI C, CAVRINI V, ANDRISANO V: β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. (2003) 65(3):407-416.
   PubMed Web of Science ®Google Scholar
• KUME T, SUGIMOTO M, TAKADA Y et al.: Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur. J. Pharmacol. (2005) 527(1-3):77-85.
   PubMed Web of Science ®Google Scholar
• TAKADA Y, YONEZAWA A, KUME T et al.: Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. (2003) 306(2):772-777.
   PubMed Web of Science ®Google Scholar
• GOTTWALD MD, ROZANSKI RI: Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status. Expert Opin. Investig. Drugs (1999) 8(10):1673-1682.
   PubMedGoogle Scholar
• WEINSTOCK M, RAZIN M, CHOREV M, TASHMA Z: Advances in Behavioral Biology. Lachman C (Ed.) Plenum Press, New York (1986):539-551.
   Google Scholar
• WILLIAMS BR, NAZARIANS A, GILL MA: A review of rivastigmine: a reversible cholinesterase inhibitor. Clin. Ther. (2003) 25(6):1634-1653.
   PubMed Web of Science ®Google Scholar
• ENZ A, AMSTUTZ R, BODDEKE H, GMELIN G, MALANOWSKI J: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Prog. Brain Res. (1993) 98:431-438.
   PubMed Web of Science ®Google Scholar
• BULLOCK R: The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int. J. Clin. Pract. (2002) 56(3):206-214.
   PubMedGoogle Scholar
• KODAMA S, HAMASHIMA Y, NISHIDE K, NODE M: Natural product synthesis: total synthesis of (-)-galanthamine by remote asymmetric induction. Angewandte Chemie Int. Ed. (2004) 43(20):2659-2661.
   PubMedGoogle Scholar
• SCHMITT B, BERNHARDT T, MOELLER HJ, HEUSER I, FROLICH L: Combination therapy in Alzheimer’s disease: a review of current evidence. CNS Drugs (2004) 18(13):827-844.
   PubMed Web of Science ®Google Scholar
• XIONG G, DORAISWAMY PM: Combination drug therapy for Alzheimer’s disease: what is evidence-based, and what is not? Geriatrics (2005) 60(6):22-26.
   PubMedGoogle Scholar
• YAMAMURO A, AGO Y, MAEDA S et al.: Protective effect of T-588 on toxic damage by serum deprivation and amyloid-β protein in cultured neurons. J. Pharmacol. Sci. (2003) 92(2):153-156.
   PubMedGoogle Scholar
• BIRKS J, GRIMLEY EV, VAN DONGEN M: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. (2002) 4:CD003120.
   PubMedGoogle Scholar
• SHOBAB LA, HSIUNG GY, FELDMAN HH: Cholesterol in Alzheimer’s disease. Lancet Neurol. (2005) 4(12):841-852.
   PubMed Web of Science ®Google Scholar
• ZHANG HY: One-compound-multiple-targets strategy to combat Alzheimer’s disease. FEBS Lett. (2005) 579(24):5260-5264.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. (2005) 26(1):27-35.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, BUCCAFUSCO JJ: CNS targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases. J. Neural Transm. (2005) 112(4):519-537.
   PubMed Web of Science ®Google Scholar
• ROSINI M, ANDRISANO V, BARTOLINI M et al.: Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. (2005) 48(2):360-363.
   PubMed Web of Science ®Google Scholar
• MELCHIORRE C, ANDRISANO V, BOLOGNESI ML et al.: Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer’s disease. J. Med. Chem. (1998) 41(22):4186-4189.
   PubMed Web of Science ®Google Scholar
• MCGAUGH JL: Memory – a century of consolidation. Science (2000) 287(5451):248-251.
   PubMed Web of Science ®Google Scholar